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Background: Cyclic adenosine 30,50-monophosphate (cAMP) is a key regulator of many cellular processes, including
in the neuronal system, and its activity is tuned by Phosphodiesterase (PDE) activation. Further, the CC2D1A protein,
consisting of N-Terminal containing four DM14 domains and C-terminal containing C2 domain, was shown to
regulate the cAMP-PKA pathway. A human deletion mutation lacking the fourth DM14 and the adjacent C2 domain
results in Non Syndromic Intellectual Disability (NSID) also referred to as Non Syndromic Mental Retardation (NSMR).
Findings: Here we demonstrate that in Mouse Embryonic Fibroblasts (MEF) CC2D1A co-localizes with PDE4D in the
cytosol before cAMP stimulation and on the periphery after stimulation, and that the movement to the periphery
requires the full-length CC2D1A. In CC2D1A mouse mutant cells, the absence of three of the four DM14 domains
abolishes migration of the complex to the periphery and causes constitutive phosphorylation of PDE4D Serine 126
(S126) via the cAMP-dependent protein kinase A (PKA) resulting in PDE4D hyperactivity. Suppressing PDE4D activity
with Rolipram in turn restores the down-stream phosphorylation of the “cAMP response element-binding protein”
(CREB) that is defective in mouse mutant cells.
Conclusion: Our findings suggest that CC2D1A is a novel regulator of PDE4D. CC2D1A interacts directly with
PDE4D regulating its activity and thereby fine-tuning cAMP-dependent downstream signaling. Based on our in vitro
evidence we propose a model which links CC2D1A structure and function to cAMP homeostasis thereby affecting
CREB phosphorylation. We speculate that CC2D1A and/or PDE4D may be promising targets for therapeutic
interventions in many disorders with impaired PDE4D function such as NSID.
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Cyclic AMP regulates a host of cellular functions that
include the activation of cAMP-dependent protein kinase
A (PKA) that in turn regulates processes such as tran-
scription, cell growth and differentiation, metabolism and
ion channel conductivity [1,2]. Therefore, alterations in
cellular cAMP homeostasis, regulated by adenylate cy-
clases (ACs) and phosphodiesterases (PDEs) are likely to
profoundly affect these cellular processes [3]. The resting
concentration of cAMP inside mammalian cells is about* Correspondence: aaltawashi@gmail.com
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distribution, and reproduction in any medium10-7 M and extracellular signals can cause cAMP levels to
change by > 20 fold in seconds which can diffuse rapidly
(130 to 700 μm2 sec–1) [4]. In animal cells, cAMP can
exert its effects via PKA that consists of a tetrameric
holoenzyme composed by two regulatory subunits consti-
tutively linked to two catalytic subunits [5]. Upon stimu-
lation cAMP binds to the regulatory subunits, causing a
conformational change which results in the release of
catalytic subunits. Once separated, catalytic subunits
become activated and catalyze the phosphorylation of spe-
cific serines or threonines of target proteins [6]. Activated
PKA catalytic subunits (Cs) translocate to the nucleus to
phosphorylate the cyclic AMP response element (CREB)
at Serine 133 (S133) initiating the transcription of target
genes [7-10]. Compartmentalization of the cAMP active
pool occurs through the cAMP module binding to Aed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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PKA regulatory subunit(R) to specific subcellular sites by
binding AKAPs helps to assure specific phosphorylation
of specific targets and thus prevents uncontrolled phos-
phorylation. PDEs in turn reduce cAMP concentration
thereby tuning the signal down or turning it “off” [12]. A
number of distinct isotypes of PDEs modulate the ampli-
tude, length and subcellular distribution of the cAMP sig-
nal [13]. Intracellular localization of PDEs also contributes
to compartmentalization of cyclic nucleotide signaling
[14]. Activation of PKA is tuned by the activity of PDE4D
that decreases cAMP levels at the site where PKA is
located while PKA phosphorylation of PDE4D is import-
ant to fully activate PDE4 enzymes [15,16]. This balanced
system enables discrete signaling.
Recently, CC2D1A has been shown to be a novel regula-
tor of the cAMP-PKA pathway [17]. Amino acid sequence
analyses of the Coiled-coil and C2 domain-containing 1A
(CC2D1A) suggested that it consists of a C2 calcium-
dependent phospholipid-binding domain, and four con-
served Drosophila melanogaster 14 (DM14) domains
specific to this protein family with uncharacterized func-
tion(s) [18]. Mutant mice with a truncated CC2D1A show
defective cAMP-PKA activation and CREB (S133) phos-
phorylation [17].
Interestingly, in NSID patients, the CC2D1Amutant pro-
tein has only the first three of the four DM14 domains and
carriers have no physical defects but are intellectually
disabled [19,20], while themousemutant CC2D1A has only
a single intact DM14 domain causing death eight to twelve
hours after birth, pointing to an essential role of the second
and third DM14 domains. Here we set out to characterize
the role of CC2D1A during cAMP-dependent stimulation
and suggest that its specific functionmay make a promising
drug target.
Results and discussion
PDE4D co-localizes with CC2D1A before and after cAMP
signaling stimulation
CC2D1A was previously shown to associate with
PDE4D5 even in the CC2D1A mutant cells and in brain
tissue [17]. In order to characterize CC2D1A interac-
tions with PDE4D5, a series of in vitro pull-down ex-
periments were performed (Figure 1). The different
recombinant GST-tagged CC2D1A proteins (fragments
I, II, III, and VII) (Figure 1A) were immobilized on glu-
tathione beads and incubated with purified PDE4D5
(IX) (Figure 1A) and PDE4D5-binding was assessed by
western blot. PDE4D5 binds to full-length CC2D1A (I)
and the CC2D1A (III) fragments, but not to the CC2D1A
(VII) fragment suggesting that CC2D1A DM14 domains
are essential for binding PDE4D5 (Figure 1B). In addition,
CC2D1A-PDE4D5 binding was almost completely abo-
lished in the absence of the first DM14 domain (fragmentII) (Figure 1C). This is consistent with previously reported
observations that PDE4D5 can be immunoprecipitated
with the mouse CC2D1A mutant form that contains only
the first DM14 domain [17], a construct that is similar to
fragment VI. We therefore conclude, firstly, that CC2D1A
binds PDE4D5 directly and that this binding occurs on the
N-terminus and within the DM14 domains and secondly,
that the first DM14 domain is essential for the binding.
Thirdly, the C2 domain is not required for binding.
Given that firstly, CC2D1A migrates to the cell periph-
ery after cAMP-stimulation [17] and, in vitro binding of
CC2D1A to PDE4D5 (Figure 1), we tested if PDE4D co-
localizes with CC2D1A at the periphery. To test this we
stimulated wild type (wt) and CC2D1A mutant Mouse
Embryonic Fibroblast (MEF) cells with forskolin, fixed
them and co-stained them with anti-CC2D1A and anti-
PDE4D antibodies. The results show that PDE4D and
CC2D1A co-localize in the cytosol prior to stimulation
and accumulate at the cell periphery after stimulation
(Figure 2A). Additionally, although the CC2D1A - PDE4D
co-localization in the cytosol was observed in the CC2D1A
mutant cells before stimulation, accumulation at periphery
does not occur after stimulation indicating the importance
of CC2D1A and PDE4D binding in PDE4D accumulation
at the periphery (Figure 2A).
The CC2D1A-PDE4D binding regulates PDE4D activity
Since PKA phosphorylation of PDE4D (S126) causes acti-
vation [21], we investigated whether PDE4D phosphoryl-
ation was affected in CC2D1A mutant MEF cells. When
cells were stimulated with forskolin, lysed and western
blotting was performed using anti-phospho-PDE4D and
anti-PDE4D antibodies, we noted that the level of PDE4D
phosphorylation was consistently increased in the mutant
(n = 7) suggesting that PDE4D may be more active in the
mutant even before stimulation which corresponds with
CREB phosphorylation defect in the CC2D1A mutant cells
on the same western blot (Figure 2B). To validate the sam-
ple loading and the phospho-PDE4D and phospho-CREB
bands, we re-stained the same blot with anti-PDE4D and
anti-CREB (Figure 2C). Given that PDE4 activity increases
by 2–3 fold after PKA has phosphorylated PDE4D and
given our observation of PDE4D hyper phosphorylation in
CC2D1A mutant cells, we tested if CC2D1A binds PDE4D
thereby reducing phosphorylation and activation. The wt
and CC2D1A mutant MEF cells were stimulated with
forskolin for different lengths of time, then collected and
lysed, protein concentrations were normalized and en-
dogenous PDE4 activity assayed. While PDE4 activity
increases and decreases gradually with increasing time of
forskolin stimulation in wt cells, PDE4 activity is higher
in CC2D1A mutant cells even before stimulation and in-
creases rapidly after the first time point of forskolin stimu-
lation and stays elevated for longer (Figure 2D) indicating
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Figure 1 In vitro-binding of CC2D1A to PDE4D5. A. Schematic diagram of GST-CC2D1A and GST-PDE4D5 fusion constructs. B. Western blot of
in vitro binding assays of recombinant proteins CC2D1A (fragments I, III, VII and GST) and recombinant PDE4D5 (fragment IX) probed with
anti-PDE4D (upper panel) or anti-GST (middle panel and lower panel). The “Input” was purified recombinant PDE4D5 (fragment IX). C. Western
blot of in vitro binding assays of recombinant proteins CC2D1A (fragments I and II) and recombinant PDE4D5 (fragment IX) probed with
anti-PDE4D (upper panel) or anti-GST (middle panel and lower panel).
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regulation occurs as a result of CC2D1A-PDE4D binding,
we first used the PDE4D5 (IX) plasmid and the GST-
CC2D1A (I) plasmid (Figure 1) to assay PDE4D5 recom-
binant activity before and after in vitro phosphorylation by
PKA and found that PDE4D5 activity increases approxi-
mately two fold after phosphorylation by PKA (Figure 2E)
and this is consistent with the previously published data
[21,22]. Then the effect of CC2D1A-PDE4D binding on
PDE4D5 activity in vitro was examined by incubating
GST-CC2D1A (I) protein with PDE4D5 (IX) in the pres-
ence and absence of PKA. When CC2D1A was bound to
PDE4D5 the activity was not affected by PKA suggesting
that CC2D1A-binding PDE4D may prevent activation by
PKA phosphorylation (Figure 2E). This is supported by
the fact that PDE4D5 activity increased after incubation
with PKA and prior to the addition of CC2D1A (I)(Figure 2E). To further investigate if this regulation acts
by preventing the PDE4D phosphorylation by PKA, we
incubated GST- CC2D1A (I) with PDE4D5 (IX) for
in vitro binding, added PKA for in vitro phosphorylation
and western blot to examine PDE4D5 phosphorylation at
(S126). The results show that PDE4D5 phosphorylation is
dramatically reduced after binding to full-length CC2D1A
(I) (Figure 3A) while PDE4D5 phosphorylation increased
after incubation with PKA and prior to the addition of
CC2D1A (I) (Figure 3A and B). PDE4D5 (IX) activation
by PKA was assayed after interaction with different
CC2D1A fragments (Figure 1A) in vivo to determine
which DM14 domains are critical for PDE4D activity.
PDE4D5 (IX) displayed normal activity before and after ac-
tivation by PKA (Figure 3C) and could be inhibited by the
PKA inhibitor (PKI) indicating that the activity is a conse-
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Figure 2 CC2D1A regulates PDE4D activity. A. Immunocytochemistry of forskolin induction time course 0, 10 and 15 minutes of wt and
CC2D1A mutant (Δ) Mouse embryonic fibroblasts (MEF) co-stained with anti-CC2D1A and anti-PDE4D. The mouse mutant form (Δ) is similar to
fragment VI since it contains only the first DM14 domain. B. Western blot of forskolin induction time course 0, 2, 7 and 30 minutes of wt and
CC2D1A mutant (Δ) MEF cells probed with anti-CC2D1A (upper panel), anti- phospho PDE4D (middle panel) or anti-phospho CREB (lower panel)
(n = 7). C. Western blot of forskolin induction time course 0, 2, 7 and 30 minutes of wt and CC2D1A mutant (Δ) MEF (shown in B) cells probed
with anti-PDE4D (upper panel) or anti-CREB (lower panel). D. Endogenous PDE4 activity in forskolin stimulated wt and CC2D1A mutant (Δ) MEF
cells. E. In vitro recombinant basal PDE4D5 (fragment IX) activity in the presence and absence of PKA and/or CC2D1A (I).
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does not appear to effect PDE4D5 activity after pre-
incubation with the full length CC2D1A (I) and CC2D1A
(III and IV) fragments separately (Figure 3C). Although
in vitro binding results confirm that the first DM14 domain
(Figure 1C) is essential for CC2D1A-PDE4D binding,
the results from (Figure 3C) suggest that fragment VI,
cannot prevent the increase in PDE4D5 activity after
PKA-dependent phosphorylation. The results therefore
suggest that the first three DM14 domains (fragment
IV) are required to substantially reduce of PDE4D5 ac-
tivity. Based on that, we conclude that the first three
DM14 domains are required to reach near wt regulation
of PDE4D5 activity (Figure 3C). The CC2D1A-C2 (VII)fragment does not prevent the increase in PDE4D5 activ-
ity after PKA-dependent phosphorylation (Figure 3C).
Rolipram, a PDE4 specific inhibitor restores the CREB
S133 (S133) phosphorylation in CC2D1A mutant cells
Since PDE4 is more active in CC2D1A mutant cells, we
hypothesized that suppressing PDE4 activity may com-
pensate for the defective phosphorylation of the PKA
target CREB at (S133) in CC2D1A mutant cells [17]. To
test this we treated wt and CC2D1A mutant MEF cells
with a PDE4 specific inhibitor Rolipram [23] prior to
stimulation with forskolin, monitored subsequent CREB
phosphorylation at (S133). Intriguingly, the results indi-
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Figure 3 Mapping of the function of DM14 domains. A. Western blot of recombinant PDE4D5 protein (fragment IX) probed with anti-
phospho PDE4D or anti-PDE4D in the presence and absence of PKA or CC2D1A (I). B schematic diagram of PDE4D phosphorylation at (S126) by
PKA in the presence and absence of CC2D1A. C. In vitro PDE4D activity assay of recombinant PDE4D5 (IX) after pre-incubation with BSA, PKI
(specific PKA inhibitor) or CC2D1A (fragments I, II, III, IV, V, VI, VII) in the presence and absence of PKA. BSA was used as a control to validate the
specificity of the responses of the different CC2D1A constructs on the inhibition of PDE4D5 activity in the presence of PKA.
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PDE4-hyper activity in the mutant might be lowering the
cAMP levels leading to defective PKA activity and thereby
defective CREB (S133) phosphorylation (Figure 4A).
The cAMP-dependent signaling is essential for many
cellular processes including cellular homeostasis anddevelopment [24,25]. Consequently, spatial and temporal
regulation of cellular cAMP concentrations needs to be
maintained under tight control. This control is largely
exerted by PDEs [26] and more recently, CC2D1A has
also been implicated in the control of cAMP homeostasis
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Figure 4 Model of CC2D1A-PDE4D interactions. A. Western blot of time course forskolin induction (0, 2, 7 and 30 minutes) of wt and CC2D1A
mutant (Δ) MEF cells after pre incubation with Rolipram, a specific PDE4 inhibitor, probed with anti-phospho CREB (S133) or anti-CREB. B. Schematic
model of the mechanism by which CC2D1A regulates the negative feedback mediated by PDE4D.
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amino acid sequence comparisons, but their biochemical
and cellular functions have remained elusive [20,27].
While essential and sufficient for binding, the first
DM14 of CC2D1A is not sufficient to confer wt function.
Humans lacking the fourth DM14 domain of CC2D1A
are intellectually disabled but have no other discernible
symptoms suggesting that CC2D1A-dependent regulation
is particularly critical in developing neural tissue. In turn,
the mouse with a CC2D1A mutation that lacks all but the
first DM14 has an even more severe phenotype causing
death shortly after birth [17]. The results suggest that the
absence of DM14 domains 2 and 3 leads to PDE4D hyper-
phosphorylation at (S126), a reaction that is catalyzed by
PKA. This hyper-phosphorylation leaves PDE4D constitu-
tively activated and consequently disturbs cAMP homeo-
stasis and cAMP-dependent downstream processes and
notably CREB phosphorylation at (S133). The latter can be
restored by the PDE4 inhibitor Rolipram suggesting that
suppressing PDE4D activity may alleviate the effects of the
defective phosphorylation of the PKA target CREB at
(S133) in CC2D1A mutant cells. If CREB phosphorylation
is disturbed, it is likely to lead to neural defects and abnor-
mal brain development causing impairments in mental
function [10]. The fact that Rolipram has therapeutic
benefits as an antidepressant and as an antipsychoticum
[28] is further indirect evidence that PDE4D may play a
key role in the nervous system and it is noteworthy thatdisturbances in intracellular cAMP levels and PKA-
dependent CREB phosphorylation have recently been
reported to cause defects in neural crest lineages which in
turn manifest themselves as Familial Dysautonomia (FD)
syndrome [29]. Given that the mutant CC2D1A protein in
NSID patients has the first three DM14 domains intact
but is lacking the fourth, we believe that the fourth do-
main also has a role in CC2D1A regulating PDE4D5 and
may be causative for the human syndrome. We speculate
that CC2D1A binding to phospholipids [17] at the mem-
brane introduces conformational changes exposing the
PDE4D5 (S126) allowing its phosphorylation and activa-
tion. Indeed, our ongoing research indicates that the
fourth DM14 domain assures the correct in vivo CC2D1A
configuration prior to binding to the phospholipid. If this
configuration is impaired it is likely to affect PDE4D5
regulation in vivo, and with it cellular cAMP homeostasis.
However, the biological role and molecular mechanism of
the fourth DM14 domain awaits further testing in vivo.
Here we propose a model (Figure 4B) that links spatial
observations to structural and functional aspects of
cAMP-dependent phosphorylation. Spatial association of
CC2D1A with PDE4D both in the cytosol and, after
cAMP stimulation, at the periphery suggests that the
common localization may be part of cAMP homeostasis
and the regulation of cAMP-dependent processes. In the
proposed model for PDE4D5 regulation, upon activation
of the adenylate cyclase, cAMP levels increase and cAMP-
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complex relocates to the plasma membrane along a cAMP
gradient where CC2D1A will prevent the early PDE4D
phosphorylation and activation by PKA. At the mem-
brane, CC2D1A anchors the complex to the cell mem-
brane by binding phospholipids and modulate PKA
activity by keeping PDE4D5 inactive for longer allowing a
longer signal duration (Figure 4B). Binding of the C2 do-
main of the CC2D1A to a membrane phospholipid [17]
might cause conformational changes in CC2D1A exposing
the (S126) residue of PDE4D5 that in turn will be activated
by the catalytic subunit of PKA that is released after
cAMP activation (Figure 4B). Binding of CC2D1A to the
phospholipid un-protects (S126), allowing PDE4D5 activa-
tion that then reduces cAMP levels and turns the signal
“off”. We propose that CC2D1A regulates the cAMP/PKA
pathway through fine-tuning the negative feedback loop
that acts via PKA activation of PDE4D. When this path-
way is defective, e.g. during neuronal development, it may
lead to a state of compromised dendrite growth, synapse
formation and neuronal survival [17] and this in turn may
be a cause of NSID.
Given that constitutive PDE4D phosphorylation at the
PKA site leads to higher enzymatic activity in CC2D1A
mutant cells, we propose that CC2D1A has a role in
preventing early PDE4D (hyper-) phosphorylation and
activation which in turn would enable higher amplitude
of cAMP and longer signal duration to exert the full
function effects. Our finding revealed the uncharac
terized function of the DM14 domain that, if proven
in vivo, may be used in the future as a target for novel
therapeutic agents in treatment of diseases caused by
PDE4D5-linked disorders.
Conclusion
The findings presented here suggest that CC2D1A with
its DM14 domains is a novel regulator of PDE4D and
that specific and spatially correct binding of CC2D1A to
PDE4D regulates the activity of the phosphodiesterase that
is necessary for fine-tuning cAMP-dependent downstream
signaling. We speculate that CC2D1A may be a promising
target for therapeutic interventions in conditions with im-
paired PDE4D5 function such as NSID.
Material and methods
Glutathione S-transferase (GST)-CC2D1A fusion protein
A BamHI-EcoRI cDNA fragments encoding the proteins
and protein fragments (see Figure 1) cloned into the
vector pGEX-4T1 using CC2D1A cDNA in a V5 vector
as template. The PCR product and pGEX-4T were
digested with BamHI and EcoRI, gel purified, and ligated
over night at 16°C. Ligated plasmids were transformed
into E. coli DH5α and plated on agarose gel plateswith Ampicillin for selection. For GST-fusion protein
purification, overnight cultures of the pGEX-CC2D1A
strains were grown in Luria-Bertani broth (LB) with 50
μg/ml of Ampicillin to an optical density of 0.45 at 600
nm. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was
added to a final concentration of 0.4 mM, and the mixture
was placed in a shaker at 37°C for 4 h. Cells were pelleted
and resuspended in 5 ml of phosphate-buffered saline
(PBS) plus protease inhibitors (0.5 mM phenylmethyl-
sulfonyl fluoride, 0.8 mg/ml leupeptin, 0.8 mg/ml pep-
statin, and 0.1 mM EDTA) and the mixture was left on ice
for 10 min. and then sonicated three times for 10 seconds
each. Triton X-100 was then added to a final concentra-
tion of 0.1%, and the lysate was shaken gently at 4°C for
30 min. Cell debris was cleared by centrifugation at 15,000
rpm at 4°C for 30 min., and the supernatant was trans-
ferred to a new microcentrifuge tube with 100 μl of 5%
slurry glutathione-conjugated beads. The lysate-GST bead
slurry was incubated for 1 h at 4°C with gentle rocking.
After that, the slurry was centrifuged at 1,000 rpm for
30 s, the supernatant was removed, and the beads were
gently resuspended in 500 μl PBS. The centrifugation-
resuspension was repeated three times to wash the beads
free of most contaminating lysate proteins. The GST
beads were then resuspended in 100 μl of PBS for further
use. To cleave the GST tag from the proteins biotinylated
Thrombin (Novagen) was used. First, 10 μl of thrombin
was added (1 unit/μl in 50 mM sodium citrate, pH 6.5,
200 mM NaCl, 0.1% Polyethylene glycol (PEG)-8000, 50%
glycerol) to the 200 μl of the bead slurry (100 μl beads and
100 μl PBS), followed by 20 μl of 10X thrombin cleavage
buffer (200 mM Tris–HCl pH 8.4, 1.5 M NaCl, 25 mM
CaCl2) and the mixture was gently shaken at room
temperature for 8 h. To capture the thrombin, 200 μl of
streptavidin agarose beads (50% slurry, Novagen) were added
to each sample and incubated with gently shaking at room
temperature for 30min. After that, samples were centrifuged
at 500 × g for 3 min. and the supernatant containing the
cleaved protein was transferred to a new tube.Analysis of signaling pathways in cultured cells
Cells were stimulated with Forskolin (Sigma) for 5, 10,
15 and 30 min., washed in cold PBS and collected. For
inhibition of PDE4 within cells, wild-type and CC2D1A
mutant MEF cells were treated with 10 μM Rolipram for
20 min. then stimulated with 20 μM forskolin for 2, 7,
and 30 min. Whole cell lysates (15 μg of protein) were
separated by SDS-PAGE gel and transferred to nitrocel-
lulose membranes. The membranes were incubated for 1
h at room temperature, or overnight at 4°C, in the corre-
sponding primary and secondary antibodies membranes
developed using the enhanced chemiluminescence (ECL)
detection system (Amersham Biosciences).
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Cells were cultured on poly-D-lysine-coated cover slips
and after experimental treatments the cells were fixed
with 4% paraformaldehyde in PBS for 10 min. at room
temperature, washed 3 times with PBS, incubated for 20
min. at 37°C in PBS containing 5% goat serum, prior to
adding the Anti-PDE4D and Anti-CC2D1A primary anti-
bodies. Following three washes with PBS, the coverslips
were incubated for 20 min. at 37°C with the Texas Red
and Fluorescein isothiocyanate (FITC) conjugated secon-
dary antibody (1/300 dilution, Chemicon). After three
washes with PBS the cover slips were incubated for 5 min.
on ice in PBS containing 50 μg/ml of 4′,6-diamidino-
2-phenylindole (DAPI), then washed three times with PBS
and mounted on glass slides. Antibody signals were visual-
ized with a Delta Vision de-convolution microscope.
In vitro protein binding assay
We obtained a GST-PDE4D5 plasmid from Graeme B.
Bolger (University of Alabama Comprehensive Cancer
Center). GST-PDE4D5 (VIII) protein was expressed and
purified and cleaved as described above. The four GST-
tagged CC2D1A (I, II, III, and IV) proteins that were
previously purified on GST beads, and the purified
PDE4D5 (IX) protein, were used as follows. The PDE4D5
(IX) (20 μg) was added to the 200 μl of the GST bead
solution with bound GST-CC2D1A (I), GST-CC2D1A
(II), GST-CC2D1A (III), or GST-CC2D1A (IV) separately.
After incubation at 4°C for 4h, samples were centrifuged
at 500 x g for 1 min. and the supernatant was removed.
Washing with PBS and centrifugation were repeated three
times and the PBS from the last wash was totally removed.
Samples were boiled at 95°C with 30 μl of protein loading
buffer for 5 min. To assess binding, 20 μl of each sample
was loaded on an SDS-PAGE gel and duplicate western
blots were made and stained with anti-PDE4D affinity-
purified rabbit antibody (1/500; FabGennix), or anti-GST
mouse monoclonal antibody (GenScript) separately.
PDE4 Assay
Thewt and CC2D1AmutantMouse Embryonic Fibroblasts
(MEF) cells were stimulated with Forskolin, processed and
the broken up by sonication. Phosphorylation of the GST-
PDE4D5 recombinant protein was assessed after PKA
treatment and exposure to ATP (Assay Designs). PDE4 ac-
tivity was measured using the PDE4 Enzymatic Assay Kit
(FabGennix) according to the manufacture’s protocol.
(The methods applied here are further detailed in the
Additional file 1).Additional file
Additional file 1: Materials and Methods.Abbreviations
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